These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 19303570)

  • 41. Prevalence of Clostridium difficile in the environment in a rural community in Zimbabwe.
    Simango C
    Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1146-50. PubMed ID: 16698054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infection of hamsters with historical and epidemic BI types of Clostridium difficile.
    Razaq N; Sambol S; Nagaro K; Zukowski W; Cheknis A; Johnson S; Gerding DN
    J Infect Dis; 2007 Dec; 196(12):1813-9. PubMed ID: 18190262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antimicrobial susceptibility of Clostridium difficile clinical isolates collected from 2001 to 2007 in a French university hospital].
    Cattoir V; Ould-Hocine ZF; Legrand P
    Pathol Biol (Paris); 2008; 56(7-8):407-11. PubMed ID: 18845403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile.
    Péchiné S; Janoir C; Boureau H; Gleizes A; Tsapis N; Hoys S; Fattal E; Collignon A
    Vaccine; 2007 May; 25(20):3946-54. PubMed ID: 17433506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model.
    Geeraerts S; Ducatelle R; Haesebrouck F; Van Immerseel F
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1275-80. PubMed ID: 25800047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-toxigenic
    Gerding DN; Sambol SP; Johnson S
    Front Microbiol; 2018; 9():1700. PubMed ID: 30093897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Epidemic risk of disease associated with a new strain of Clostridium difficile].
    Arteaga A; Santa-Olalla P; Sierra MJ; Limia A; Cortés M; Amela C
    Enferm Infecc Microbiol Clin; 2009 May; 27(5):278-84. PubMed ID: 19386385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study of the thermoresistance of Clostridium difficile spores].
    Meisel-Mikołajczyk F; Kaliszuk-Kamińska E; Martirosian G
    Med Dosw Mikrobiol; 1995; 47(3-4):177-81. PubMed ID: 8833929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New trends in Clostridium difficile virulence and pathogenesis.
    Denève C; Janoir C; Poilane I; Fantinato C; Collignon A
    Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S24-8. PubMed ID: 19303565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Susceptibility of Clostridium difficile to metronidazole using the E-test: effect of the culture medium].
    Poilane I; Cruaud P; Rousseau JG; Torlotin JC; Collignon A
    Pathol Biol (Paris); 1999 May; 47(5):515-8. PubMed ID: 10418031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Measures to control and prevent Clostridium difficile infection.
    Gerding DN; Muto CA; Owens RC
    Clin Infect Dis; 2008 Jan; 46 Suppl 1():S43-9. PubMed ID: 18177221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emergence of reduced susceptibility to metronidazole in Clostridium difficile.
    Baines SD; O'Connor R; Freeman J; Fawley WN; Harmanus C; Mastrantonio P; Kuijper EJ; Wilcox MH
    J Antimicrob Chemother; 2008 Nov; 62(5):1046-52. PubMed ID: 18693234
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of Clostridium difficile-associated disease.
    Leffler DA; Lamont JT
    Gastroenterology; 2009 May; 136(6):1899-912. PubMed ID: 19457418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.
    Ribes S; Taberner F; Domenech A; Cabellos C; Tubau F; Liñares J; Viladrich PF; Gudiol F
    J Antimicrob Chemother; 2006 May; 57(5):931-6. PubMed ID: 16507562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects.
    Villano SA; Seiberling M; Tatarowicz W; Monnot-Chase E; Gerding DN
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5224-9. PubMed ID: 22850511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of age, dose and antibiotic therapy on the development of Clostridium difficile infection in neonatal piglets.
    Arruda PH; Madson DM; Ramirez A; Rowe E; Lizer JT; Songer JG
    Anaerobe; 2013 Aug; 22():104-10. PubMed ID: 23624068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen.
    Péchiné S; Denève C; Le Monnier A; Hoys S; Janoir C; Collignon A
    FEMS Immunol Med Microbiol; 2011 Oct; 63(1):73-81. PubMed ID: 21707776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clostridium difficile infection in solid organ transplant recipients.
    Riddle DJ; Dubberke ER
    Curr Opin Organ Transplant; 2008 Dec; 13(6):592-600. PubMed ID: 19060548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Interest of the disk diffusion method for screening Clostridium difficile isolates with decreased susceptibility to antibiotics].
    Poilane I; Bert F; Cruaud P; Nicolas-Chanoine MH; Collignon A
    Pathol Biol (Paris); 2007 Nov; 55(8-9):429-33. PubMed ID: 17905536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In-vitro and in-vivo characterisation of resistance to colonisation with Clostridium difficile.
    Larson HE; Welch A
    J Med Microbiol; 1993 Feb; 38(2):103-8. PubMed ID: 8429534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.